Home › Calculator › EVLO Dividend Calculator 2026
EVLO Dividend DRIP Calculator 2026
2000000.00% YieldHealthcareEvelo Biosciences, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When EVLO pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your EVLO snowball 📈
$10,000 in EVLO → $1.0245121152153611e+41M in 10 years · $8,537,174,101,422,937,000,000,000,000,000,000,000,000,000,000.00/month
About Evelo Biosciences, Inc. (EVLO) — Dividend Analysis 2026
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
Compare EVLO with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full EVLO DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open EVLO position with:
🌍 EVLO Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold EVLO.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1700000.00% | 1699997.20% | $170,000,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1600000.00% | 1599997.20% | $160,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1825000.00% | 1824997.20% | $182,500,000 / yr |
| 🇨🇦 TFSA | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 1500000.00% | 1499997.20% | $150,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 1700000.00% | 1699997.20% | $170,000,000 / yr |
| 🇦🇺 AU Taxable | 30% | 1400000.00% | 1399997.20% | $140,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1472500.00% | 1472497.20% | $147,250,000 / yr |
| 🇫🇷 FR Taxable | 30% | 1400000.00% | 1399997.20% | $140,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 EVLO Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 EVLO Dividend Payment Schedule
EVLO pays quarterly — 4 times per year. Next ex-div: TBD.
📊 EVLO vs Healthcare Benchmarks
How EVLO compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for EVLO sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ EVLO Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2023-11-07 | 6,625 | — | — | ||
| Sale | 2023-11-08 | 3,163 | $0.33 | $1.0K | ||
| M-Exempt | 2023-11-07 | 6,625 | — | — | ||
| M-Exempt | 2023-11-07 | 6,500 | — | — | ||
| Sale | 2023-11-08 | 3,103 | $0.33 | $1.0K | ||
| M-Exempt | 2023-11-07 | 6,500 | — | — | ||
| M-Exempt | 2023-11-07 | 1,172 | — | — | ||
| Sale | 2023-11-08 | 172 | $0.33 | $57.00 | ||
| M-Exempt | 2023-11-07 | 1,172 | — | — | ||
| M-Exempt | 2023-11-07 | 6,500 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the EVLO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Evelo Biosciences, Inc. (EVLO) is currently trading at $0.00, trading near its 52-week low. The current dividend yield is 2000000.00% based on an annual payout of $2.00 per share.
EVLO (Evelo Biosciences, Inc.) — 2000000.00% Dividend Yield Analysis
Evelo Biosciences, Inc. (EVLO) is a healthcare stock currently trading at $0.00 with a dividend yield of 2000000.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (2000000.00%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.